# BridgeBio Pharma (BBIO) — News

BBIO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/bbio/news

## Recent headlines

- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610-19) — AInvest Wire, Oct 13, 2026
  Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…
- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610) — AInvest Wire, Oct 13, 2026
- [Encaleret increased bone turnover and improved participant-reported symptoms in the phase 3 Calibrate trial in ADH1](https://www.ainvest.com/news/encaleret-increased-bone-turnover-improved-participant-reported-symptoms-phase-3-calibrate-trial-adh1-2610) — AInvest Wire, Oct 11, 2026
  BridgeBio Pharma’s Calcilytix Therapeutics recently announced topline results from its Phase 3 CALIBRATE trial of encaleret, an oral therapy under development for individuals with autosomal dominant hypocalcemia type 1 . The trial demonstrated that encaleret increased bone turnover and improved…
- [BridgEBio Pharma - Anticipates U.S. launch of oral infigratinib upon approval](https://www.ainvest.com/news/bridgebio-pharma-anticipates-launch-oral-infigratinib-approval-2610) — AInvest Wire, Oct 6, 2026
- [Bridgepharma - 100% of BBP-418-treated LGMD2I/R9 patients normalize HS troponin I at month 12](https://www.ainvest.com/news/bridgepharma-100-bbp-418-treated-lgmd2i-r9-patients-normalize-hs-troponin-month-12-2610) — AInvest Wire, Oct 5, 2026
  Bridgepharma Inc. (NASDAQ: BBIO) reported positive clinical outcomes for its investigational therapy BBP-418 in patients with limb-girdle muscular dystrophy type 2I (LGMD2I/R9). According to the company’s 2020 annual report filed with the U.S. Securities and Exchange Commission, data from the…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).